Altogether, this work supports the idea that reduced levels of CD16+ CD56- HLA-DR+ NK cells in those that will experience a more severe COVID-19 could be due to the fact that the SARS-CoV-2 infection triggers alterations in NK and, subsequently, the dysfunction and apoptosis of these cells. The gene discussed is NCAM1; the disease is COVID-19.